Post Spotlights ICER’s Remdesivir Pricing Models
May 24, 2020
The authors of a recent Health Affairs blog post highlight the Institution for Clinical and Economic Review’s (ICER) pricing recommendations for Gilead’s remdesivir.
ICER’s value-based price for the drug raises several questions, the authors, Joshua Cohen, Peter Neumann and Daniel Ollendorf, write, including the exclusion of societal benefits.
“Ignoring remdesivir’s potential non-health benefits also seems a glaring omission, as the United States nears two months of shutdown, a main goal of which has been to ‘flatten the curve’ and hence protect the health care system from becoming overwhelmed,” they write.
To read the full blog post, click here.
